DexCom (DXCM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.70
- Estimate
- $0.61
- Surprise
- +15.1%
- Revenue (period 2026-06-30)
- $1.31B
- Score at report (before → after)
- 6.6 → 6.7/10
Revenue source: xbrl.
How the report landed
DexCom (DXCM) beat the $0.61 estimate with diluted EPS of $0.70 — a large 15.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.6/10) to Hold at 6.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DXCM Buy (Wait) at 6.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +15.1% surprise compares with a +11.5% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.5 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: CGM systems
- Concentration risk — Supplier: single- or sole-source suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $83.03
- Entry target
- $73.98
- Price target
- $84.71
- Stop
- $69.20
- Upside to target
- +2.0%
- Reward-to-risk
- 0.3:1
The stock trades at 32.8× trailing but 26.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 19 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
DXCM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $31.33B
- P/E (fwd)
- 26.6
- P/E (ttm)
- 32.8
- 52-week range
- $54.11–$92.59
- Off 52-week high
- 10.3%
- RSI (14)
- 19
- Volume vs avg
- 0.67×
- Score today
- 6.4/10